Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: A global developer, manufacturer, and marketer of specialized apparatus and scientific instruments for life science research. The company focuses on two primary application areas: ADMET testing and molecular biology/liquid handling. Operations are conducted in the U.S., U.K., Germany, Spain, France, and Canada.
Key Financial Metrics
| Metric | 2009 | 2008 | 2007 |
|---|---|---|---|
| Revenues | $85.8 million | $88.0 million | $83.4 million |
| Gross Profit | $41.7 million | $42.2 million | $40.2 million |
| Gross Margin | 48.6% | 47.9% | 48.3% |
| Operating Income | $8.1 million | $8.5 million | $9.5 million |
| Net Income | $7.2 million | $1.7 million | ($1.4 million) |
| Diluted EPS | $0.24 | $0.05 | ($0.04) |
| Cash and Equivalents | $16.6 million | $13.7 million | $17.9 million |
| Long-Term Debt | $13.3 million | $0.1 million | $5.6 million |
| Working Capital | $35.9 million | $32.2 million | $38.0 million |
Operating Cash Flow: $16.5 million (2009) vs. $9.2 million (2008).
Capital Expenditures: $1.4 million (2009).
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 2.6% to $85.8 million. This decline was driven by a 5.4% negative impact from the strengthening U.S. dollar and a 5.8% decrease in organic growth due to the global recession. These factors were partially offset by $7.6 million in revenue from the September 2009 acquisition of Denville Scientific, Inc.
- Profitability Improvement: Despite lower revenues, Net Income increased significantly from $1.7 million in 2008 to $7.2 million in 2009. This was largely due to a $2.6 million pre-tax gain from the adjustment of contingent consideration related to the Denville acquisition and improved gross margins (48.6% vs. 47.9%).
- Debt Increase: Long-term debt increased to $13.3 million from negligible levels in 2008. Borrowings were utilized to fund the Denville acquisition.
- Discontinued Operations: The company recorded a $0.1 million gain in discontinued operations in 2009, compared to a $3.7 million loss in 2008, reflecting the finalization of the divestiture of the Capital Equipment Business segment.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management maintains a strategy of "tuck-under" acquisitions combined with organic growth. The acquisition of Denville is expected to be a significant contributor to future organic growth, providing access to the $1 billion laboratory consumables market. The company plans to continue investing in new product development, including the PHD Ultra syringe pumps and regenerative medicine products.
Liquidity & Capital Resources: The company has a $20.0 million revolving credit facility (maturity August 2012) with $6.7 million available as of year-end. Management believes current cash, operating cash flow, and debt capacity are sufficient to finance operations for at least 12 months.
Key Risks & Contingencies:
- Customer Concentration: GE Healthcare accounted for 12% of 2009 revenues. The company relies on distribution agreements with GE Healthcare for significant product lines (Biochrom and Hoefer).
- Foreign Exchange: Approximately 52% of revenues are derived from non-U.S. operations. A strengthening U.S. dollar negatively impacts reported revenues and earnings.
- Acquisition Integration: Risks associated with integrating Denville and realizing anticipated benefits.
- Economic Conditions: Continued global economic uncertainty may delay customer purchasing decisions.
- Contingent Consideration: A final payment of approximately $1.9 million is due in Q2 2010 for the Denville acquisition; deviations from estimates could impact 2010 results.
Investor Verification Checklist
- Denville Integration: Verify the progress of integrating Denville Scientific and whether it is meeting revenue and margin expectations.
- GE Healthcare Relationship: Monitor the status of distribution agreements with GE Healthcare, which represents a material portion of revenue.
- Foreign Currency Exposure: Assess the impact of U.S. dollar fluctuations on future earnings, given the high percentage of international sales.
- Debt Covenants: Confirm continued compliance with the financial covenants of the $20 million credit facility.
- Regenerative Medicine: Evaluate the commercial viability and regulatory progress of new products in the regenerative medicine sector.